Panelists discuss how bimekizumab demonstrated significant improvements in pain scores (from baseline levels around 60/100) and fatigue measures, with meaningful percentages of patients achieving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback